Tested two lymphoma cell therapies for relapsed or resistant cancer
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies two investigational cell therapies (KITE-363 or KITE-753) in people whose B-cell lymphoma has returned or did not respond to prior treatment. The goal is to see how safe the treatments are and how well they can shrink the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have relapsed or refractory B-cell lymphoma (your lymphoma came back or is not responding).
- You have at least one measurable spot of lymphoma that doctors can measure on scans.
- Your organs and bone marrow are working well enough for chemotherapy and treatment.
- You have not had CAR T-cell therapy or other genetically modified T-cell therapy before.
- You do not have certain recent or ongoing cancers, transplants, or serious active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR T-cell therapy, KITE-753, against an approved one, Yescarta (axicabtagene ciloleucel), for people with large B-cell lymphoma that came back or didn't respond to first-line treatment. The goal is to see which works better.
This trial tests a new cell therapy, KITE-753, for adults with B-cell acute lymphoblastic leukemia (ALL) that has come back or not responded to treatment. It aims to see if this therapy can help control the disease.
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
This trial tests a new cell therapy called KITE-363 for people with certain autoimmune diseases (lupus, lupus nephritis, systemic sclerosis, or idiopathic inflammatory myopathy) that haven't improved with standard treatments. It aims to see if this therapy can help control the disease.
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
This trial tests a new type of CAR-T cell therapy for people with certain B-cell lymphomas that have come back or not responded to treatment. The CAR-T cells are made from a donor and are genetically edited to possibly work better and last longer.
Hear when a new Relapsed and/or Refractory B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.